{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:24Z","timestamp":1792887804033,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.braindev.2023.12.001","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T13:00:01Z","timestamp":1702645201000},"page":"149-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function"],"prefix":"10.1016","volume":"46","author":[{"given":"Yuki","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Narugami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Nakakubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.braindev.2023.12.001_b0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.braindev.2023.12.001_b0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nn.4508","article-title":"Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy","volume":"20","author":"Corey","year":"2017","journal-title":"Nat Neurosci"},{"issue":"9","key":"10.1016\/j.braindev.2023.12.001_b0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.braindev.2017.04.018","article-title":"Relationships between long-term observations of motor milestones and genotype analysis results in childhood-onset Japanese spinal muscular atrophy patients","volume":"39","author":"Kaneko","year":"2017","journal-title":"Brain Dev"},{"issue":"3","key":"10.1016\/j.braindev.2023.12.001_b0020","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.braindev.2023.12.001_b0025","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.braindev.2023.12.001_b0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"issue":"18","key":"10.1016\/j.braindev.2023.12.001_b0035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.braindev.2023.12.001_b0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/mus.27187","article-title":"Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study","volume":"63","author":"Acsadi","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.braindev.2023.12.001_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data","volume":"39","author":"Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.braindev.2023.12.001_b0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0887-8994(90)90072-9","article-title":"Attenuated SEPs with no latency shifts in a family with hereditary spastic paraplegia","volume":"6","author":"Imai","year":"1990","journal-title":"Pediatr Neurol"},{"issue":"14","key":"10.1016\/j.braindev.2023.12.001_b0055","doi-asserted-by":"crossref","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","article-title":"Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study","volume":"91","author":"Aragon-Gawinska","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.braindev.2023.12.001_b0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.25533","article-title":"Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data","volume":"86","author":"Pane","year":"2019","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.braindev.2023.12.001_b0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany","volume":"5","author":"Pechmann","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"10.1016\/j.braindev.2023.12.001_b0070","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.braindev.2023.12.001_b0075","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.21838","article-title":"Compound muscle action potential and motor function in children with spinal muscular atrophy","volume":"42","author":"Lewelt","year":"2010","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.braindev.2023.12.001_b0080","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.braindev.2023.12.001_b0085","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41436-020-00987-w","article-title":"CMAP changes upon symptom onset and during treatment in spinal muscular atrophy patients: lessons learned from newborn screening","volume":"23","author":"Weng","year":"2021","journal-title":"Genet Med"},{"issue":"Pt A","key":"10.1016\/j.braindev.2023.12.001_b0090","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2018.02.022","article-title":"Spinal muscular atrophy: Selective motor neuron loss and global defect in the assembly of ribonucleoproteins","volume":"1693","author":"Beattie","year":"2018","journal-title":"Brain Res"},{"issue":"10","key":"10.1016\/j.braindev.2023.12.001_b0095","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.braindev.2023.12.001_b0100","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0729","article-title":"Gene therapy for spinal muscular atrophy: Safety and early outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.braindev.2023.12.001_b0105","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy: Nusinersen clinical trial experience","volume":"31","author":"Hach\u00e9","year":"2016","journal-title":"J Child Neurol"},{"issue":"9","key":"10.1016\/j.braindev.2023.12.001_b0110","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic Spinal Muscular Atrophy (SMA) treated with Nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.braindev.2023.12.001_b0115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.braindev.2021.08.002","article-title":"Epidemiological investigation of spinal muscular atrophy in Japan","volume":"44","author":"Ito","year":"2022","journal-title":"Brain Dev"},{"issue":"8","key":"10.1016\/j.braindev.2023.12.001_b0120","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/00207454.2021.1995382","article-title":"Real-world safety of nusinersen in Japan: results from an interim analysis of a post-marketing surveillance and safety database","volume":"133","author":"Wataya","year":"2023","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.braindev.2023.12.001_b0125","doi-asserted-by":"crossref","unstructured":"Tachibana Y, Takasaki S, Hoshino M, Makioka H, Jin M. Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance. Int J Neurosci. 2022, in press. doi: 10.1080\/00207454.2022.2095270.","DOI":"10.1080\/00207454.2022.2095270"},{"key":"10.1016\/j.braindev.2023.12.001_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.918255","article-title":"Exploratory evaluation of an eye-tracking system in patients with advanced spinal muscular atrophy type I receiving nusinersen","volume":"13","author":"Yae","year":"2022","journal-title":"Front Neurol"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760423001924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760423001924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:52:04Z","timestamp":1759953124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760423001924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0387760423001924"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2023.12.001","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2023.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}